Sheet 1 of 4

FORM PTO-1449

MENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY. DOCKET NO. SERIAL NO. 2026-4282 09/744,289 APPLICANT

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

SZU et al. FILING DATE GROUP ART UNIT TBA January 22, 2001

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
NAOP .	4,356,170	10/26/82	JENNINGS ET AL	1		
	4,711,779	12/8/87	PORRO ET AL			
	5,371,197	12/6/94	MARBURG ET AL			
	5,585,100	12/17/96	MOND ET AL			
	5,693,326	12/2/97	LEES			
	5,773,007	6/30/98	PENNY ET AL			
	5,785,973	7/28/98	BIXLER ET AL			
	5,370,872	12/6/94	CRYZ ET AL			
1 //	5,306,492	4/26/94	PORRO			
W	5,153,312	10/6/92	PORRO		7	

FOREIGN PATENT DOCUMENTS

				·		TRANSLATION	
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)



Chu, C; "Preparation, Characterization, an Immunogenicity of Conjugates Composed of the O-Specific Polysaccharide of Shigella dysenteriae Type 1 (Shiga's Bacillus) Bound to Tetanus Toxoid", Infection and Immunity, Vol. 59, No.12; pp 4450-4458, December 1991.

Cryz, S.J, "Synthesis and Characterization of Escherichia coli 018 O-Polysaccharide Conjugate Vaccines", Infection and Immunity, Vol. 58, No. 2, pp 373-377, February 1990.

Sportne 7/2/03

Sheet 3 of 4

		Sheet 3 of 4
B	/	Johnson, R.P., "Serum Antibody Responses of Cattle Following Experimental Infection with Escherichia coli O157:H7", Infection and Immunity, Vol. 64, pp 1879-1883, May 1996.
	V	Conference Discusses Ways to Reduce E. coli at Farm and Slaughter, Food Chemical News, Vol. 37, No. 9 (Abstract) April 24, 1995.
	/	E. coli, VTEC Research Reviewed at IAMFES Meeting, Food Chemical News, Vol 38, No. 21, (Abstract) July 15, 1996.
	V	/Brief Notes: Researchers at the National Institutes of Health, Food Chemical News, Vol 39, No. 52, (Abstract) February 16, 1998.
		E. coli US Experts: Food Poisoning Vaccine Works, Vaccine Weekly, (Abstract), March 2, 1998.
	/	Product News: Escherichia coli Vaccine Specific to E. coli O157 Might be Useful for Prophylaxis and Treament, <i>Inpharma</i> , (Abstract), February 24, 1998.
		You Should Know, Food Institute Report, Vol. 71, No. 7, (Abstract), February 16, 1998.
	,	Konadu et al, "Synthesis and Immunologic Properties of O-Specific Polysaccharide-Protein Conjugate Vaccines for Prevention and Treatment of Infections with Escherichia coli O157 and Other Causes of the Hemolytic-Uremic Syndrome", In Escherichia coli O157:H7 and other Shiga Toxin-Producing E. coli Strains, Ed. JB. Kaper and A.D. O'Brien, American Society for Microbiology, Washington, pp 419-424 (June 19, 1998) (based on a symposium and workshop held in Baltimore, MD, June 22-26, 1997)
		Meeting schedule and slides from presentation by Shousun C. Szu entitled "LPs-based vaccine" held on June 26, 1997 during a symposium and workshop of the American Society for Microbiology, Washington, DC, held in Baltimore, MD, June 22-26, 1997 (with re-typed text of the slide labeled "Why is conjugate better" and computer printout of "Anti-LPS IgG (Preliminary slide)
V		Claesson et al, "Clinical and Immunologic Responses to the Capsular Polysaccharide of Haemophilus Influenzae Type b Alone or Conjugated to Tetanus Toxoid in 18-to 23 month old Children", Journal of Pediatrics, Vol. 112 No. 5 pp 695-702, May 1988

BAN 7/2/83

	AP	Sheet 2 of
VBR	ATEN.	Bread al., "Glycoconjugates of Bacterial Carbohydrate Antigens a Survey and Consideration of Design and Preparation Factors", Cruse JM, Lewis RE Jr. (eds) Conjugate Vaccines, Vol. 10, pp 48-114, 1989.
		Gupta, R.K., "Comparitive Immunogenicity of Conjugates Composed of Escherichia coli 0111 0-Specific Polysaccharide, Prepared by Treatment with Acetic Acid or Hydrazine, Bound to Tetanus Toxoid by Two Synthetic Schemes", <i>Infection and Immunity</i> Vol. 63, No. 8., pp 2805-2810, August 1995.
		Konadu et al, "Investigational Vaccine for Escherichia coli 0157: Phase 1 Study of 0157 O-Specific Polysaccharide-Pseudomonas aeruginosa Recombinant Exoprotein A Conjugates in Adults", <i>The Journal of Infectious Diseases</i> . February 1998, Vol. 177, pp 383-387. (mailed out to the public on January 21, 1998).
		Konadu et al, "Preparation, Characterization, and Immunological Properties in Mice of Escherichia coli 0157 0-Specific Polysaccharide-Protein Conjugate Vaccines", <i>Infection and Immunity</i> , Vol. 62, No. 11, pp 5048-5054, November 1994.
		Robbins et al, "O-Specific Side-Chain Toxin-Protein Conjugates as Parental Vaccines for the Prevention of Shigellosis and Related Diseases", <i>Reviews of Infectious Diseases</i> , Vol. 13, No. 4 supplement, pp S362-S365, 1991.
	*	Sjogren et al, "Influence of Shiga-like toxin production in Enteric Infection with an Enteropathogenic Escherichia coli strain", <i>Gastroenterology</i> , Vol. 92, No. 5, Part 2 pp 1643, May 1987.
		Taylor et al, "Synthesis, Characterization, and Clinical Evaluation of Conjugate Vaccines Composed of the 0-Specific Polysaccharides of Shigella dysenteriae Type 1, Shigella flexneri Type 2a, and Shigella sonnei (Plesiomonas shigelloides) Bound to Bacterial Toxoids", <i>Infection and Immunity</i> , Vol. 61, pp 3678-3687, September 1993.
	+	Human Testing of E. Coli 0157:H7 Vaccine, Food Chemical News, , Vol. 37 No. 19 (Abstract), July 3, 1995.
	V	Lovett, R.A., "Training a Molecular Gun on Killer E. coli", Science 282: 1404, November 20, 1998.
7		Robbins et al, "Hypothesis for Vaccine Development: Protective Immunity to Enteric Diseases Caused by Nontyphoidal Salmonellae and Shigellae May be Conferred by Serum IgG Antibodies to the O-Specific Polysaccharide of their Lipopolysaccharides", Clinical Infectious Diseases, Vol 15 pp 346-361,1992.

Port 7/2/03

Sh	eet	1	Ωf	7
ווכ	CCL	4	UI.	-

		72,	Sheet 4 of 4
Bo		Pneumococcus Type 6B and Haem	coccus Vaccine alone or Mixed with DTP and on nophilus influenzae Type b Capsular Polysaccharide-tetanus e-year Old Children with Sickle Cell Anemia", <i>Pediaric Infect</i> .
	/	by Haemophilus Influenzae Type l	d Qualitative Analyses of Serum Antibodies Elicited in Adults o and Penumococcus Type 6A Capsular Polysaccharidection and Immunity, pp 519-528, May 1986.
			otheses: Serum IgG Antibody is Sufficient to Confer Protection ctivating the Inoculum", Journal of Infectious Diseases, Vol.
V	/		enicity of Escherichia Coli 018 O-Specific Polysaccharide (O-xin Conjugate Vaccines in Humans", <i>Journal of Infectious</i> 1, 1991.
EXAMINER			DATE CONSIDERED
		FPM ==	7/2/03
EXAMINER: through citatio	Initial n if no	if reference considered, whether or in conformance and not considered	not citation is in conformance with MPEP 609; Draw line . Include copy of this form with next communication to

M&F REV. 06/29/95

applicant.